STOCK TITAN

MeiraGTx to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
MeiraGTx Holdings plc (NASDAQ: MGTX) announced its participation in upcoming investor conferences. Alexandria Forbes, Ph.D., President, and CEO will present at Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, BofA Securities Healthcare Conference 2024, and Goldman Sachs 45th Annual Global Healthcare Conference. Live webcasts will be available on the Investors page of the Company's website.
MeiraGTx Holdings plc (NASDAQ: MGTX) ha annunciato la sua partecipazione ai prossimi convegni per investitori. La presidente e CEO, Alexandria Forbes, Ph.D., presenterà al Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, alla BofA Securities Healthcare Conference 2024 e alla Goldman Sachs 45th Annual Global Healthcare Conference. Le trasmissioni web in diretta saranno disponibili sulla pagina degli investitori del sito web della società.
MeiraGTx Holdings plc (NASDAQ: MGTX) anunció su participación en futuras conferencias para inversores. Alexandria Forbes, Ph.D., Presidenta y CEO, presentará en el Chardan 8º Simposio Anual de Medicinas Genéticas y Fabricación de Terapias Celulares, en la Conferencia de Salud de BofA Securities 2024 y en la 45ª Conferencia Global Anual de Salud de Goldman Sachs. Las transmisiones en vivo estarán disponibles en la página de Inversores del sitio web de la Compañía.
MeiraGTx Holdings plc (NASDAQ: MGTX)는 다가오는 투자자 컨퍼런스 참가를 발표했습니다. 알렉산드리아 포브스 박사, 회장 및 CEO는 Chardan 제8회 연례 유전 의학 및 세포 치료제 제조 정상회의, BofA 증권 헬스케어 컨퍼런스 2024, 그리고 골드만삭스 제45회 연례 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다. 생중계 웹캐스트는 회사 웹사이트의 투자자 페이지에서 볼 수 있습니다.
MeiraGTx Holdings plc (NASDAQ: MGTX) a annoncé sa participation aux prochaines conférences d'investisseurs. Alexandria Forbes, Ph.D., présidente et chef de la direction, présentera lors du Chardan 8ème Sommet annuel sur les médicaments génétiques et la fabrication de thérapies cellulaires, de la conférence sur la santé de BofA Securities 2024 et de la 45e conférence annuelle mondiale sur la santé de Goldman Sachs. Des webcasts en direct seront disponibles sur la page des investisseurs du site web de l'entreprise.
MeiraGTx Holdings plc (NASDAQ: MGTX) kündigte seine Teilnahme an bevorstehenden Investorenkonferenzen an. Alexandria Forbes, Ph.D., Präsidentin und CEO, wird auf dem Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, der BofA Securities Healthcare Conference 2024 und der Goldman Sachs 45th Annual Global Healthcare Conference präsentieren. Live-Webcasts werden auf der Investorenseite der Unternehmenswebsite verfügbar sein.
Positive
  • None.
Negative
  • None.

LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

  • Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, Virtual

Corporate presentation: Monday, April 29, 2024, at 11:00 a.m. ET

  •  BofA Securities Healthcare Conference 2024, Las Vegas

Corporate presentation: Wednesday, May 15, 2024, at 10:40 a.m. PT

  •  Goldman Sachs 45th Annual Global Healthcare Conference, Miami

Corporate presentation: Wednesday, June 12, 2024, at 2:40 p.m. ET

A live webcast of the corporate presentations will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

For more information, please visit www.meiragtx.com.


FAQ

When will MeiraGTx participate in the Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit?

MeiraGTx will participate in the Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024, at 11:00 a.m. ET.

What is the date and time of MeiraGTx's presentation at the BofA Securities Healthcare Conference 2024?

MeiraGTx will present at the BofA Securities Healthcare Conference 2024 on Wednesday, May 15, 2024, at 10:40 a.m. PT.

Where will MeiraGTx participate in the Goldman Sachs 45th Annual Global Healthcare Conference?

MeiraGTx will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Wednesday, June 12, 2024, at 2:40 p.m. ET.

Where can investors watch the live webcast of MeiraGTx's corporate presentations?

Investors can watch the live webcast of MeiraGTx's corporate presentations on the Investors page of the Company's website at www.investors.meiragtx.com.

For how long will replays of the corporate presentations be available?

Replays of the corporate presentations will be available for approximately 30 days following the presentation dates.

MeiraGTx Holdings plc Ordinary Shares

NASDAQ:MGTX

MGTX Rankings

MGTX Latest News

MGTX Stock Data

470.48M
46.84M
24.25%
55.13%
2.15%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK